PepGen (PEPG) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed PepGen (PEPG) over the past year, gaining 62.9% versus a loss of 51.1%. Whitehawk Therapeutics is the larger company by market cap ($200.7 million vs $181.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEPG | WHWK |
|---|---|---|
| Share price | $2.62 | $3.52 |
| Market cap | $181.22M | $200.67M |
| 1-day change | +10.08% | +1.44% |
| YTD return | -63.44% | +43.39% |
| 1-year return | -51.13% | +62.91% |
| 5-year return | — | -87.25% |
| EPS (TTM) | $-1.01 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.80 | $5.50 |
| 52-week low | $1.31 | $1.87 |
| Distance from 52-week high | -66.41% | -35.94% |
| Analyst consensus | none | buy |
| Avg. price target upside | +288.93% | +119.03% |
| Average volume | 946.80K | 367.72K |
| Shares outstanding | 69.17M | 57.01M |
| Employees | 57 | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed PEPG by 114.0 percentage points over the past year.
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
PEPG vs WHWK FAQ
Which is bigger, PepGen or Whitehawk Therapeutics?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $200.67M compared with $181.22M for PepGen (PEPG).
Which stock has performed better over the past year, PEPG or WHWK?
WHWK returned +62.91% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are PepGen and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.